163 related articles for article (PubMed ID: 38383447)
1. LATS1/2 loss promote tumor immune evasion in endometrial cancer through downregulating MHC-I expression.
Yang Q; Lv Z; Wang M; Kong M; Zhong C; Gao K; Wan X
J Exp Clin Cancer Res; 2024 Feb; 43(1):54. PubMed ID: 38383447
[TBL] [Abstract][Full Text] [Related]
2. LC3 and NLRC5 interaction inhibits NLRC5-mediated MHC class I antigen presentation pathway in endometrial cancer.
Zhan L; Zhang J; Zhang J; Liu X; Zhu S; Shi Y; He Y; Wang W; Fan Y; Tang Z; Chen G; Wei B; Cao Y
Cancer Lett; 2022 Mar; 529():37-52. PubMed ID: 34974132
[TBL] [Abstract][Full Text] [Related]
3. Selective autophagy of NLRC5 promotes immune evasion of endometrial cancer.
Zhan L; Zhang J; Wei B; Cao Y
Autophagy; 2022 Apr; 18(4):942-943. PubMed ID: 35174769
[TBL] [Abstract][Full Text] [Related]
4. NLRC5/MHC class I transactivator is a target for immune evasion in cancer.
Yoshihama S; Roszik J; Downs I; Meissner TB; Vijayan S; Chapuy B; Sidiq T; Shipp MA; Lizee GA; Kobayashi KS
Proc Natl Acad Sci U S A; 2016 May; 113(21):5999-6004. PubMed ID: 27162338
[TBL] [Abstract][Full Text] [Related]
5. Hippo-signaling-controlled MHC class I antigen processing and presentation pathway potentiates antitumor immunity.
Peng L; Zhou L; Li H; Zhang X; Li S; Wang K; Yang M; Ma X; Zhang D; Xiang S; Duan Y; Wang T; Sun C; Wang C; Lu D; Qian M; Wang Z
Cell Rep; 2024 Apr; 43(4):114003. PubMed ID: 38527062
[TBL] [Abstract][Full Text] [Related]
6. Metabolic stress in cancer cells induces immune escape through a PI3K-dependent blockade of IFNγ receptor signaling.
Marijt KA; Sluijter M; Blijleven L; Tolmeijer SH; Scheeren FA; van der Burg SH; van Hall T
J Immunother Cancer; 2019 Jun; 7(1):152. PubMed ID: 31196219
[TBL] [Abstract][Full Text] [Related]
7. Frequent Loss of IRF2 in Cancers Leads to Immune Evasion through Decreased MHC Class I Antigen Presentation and Increased PD-L1 Expression.
Kriegsman BA; Vangala P; Chen BJ; Meraner P; Brass AL; Garber M; Rock KL
J Immunol; 2019 Oct; 203(7):1999-2010. PubMed ID: 31471524
[TBL] [Abstract][Full Text] [Related]
8. Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I.
Yamamoto K; Venida A; Yano J; Biancur DE; Kakiuchi M; Gupta S; Sohn ASW; Mukhopadhyay S; Lin EY; Parker SJ; Banh RS; Paulo JA; Wen KW; Debnath J; Kim GE; Mancias JD; Fearon DT; Perera RM; Kimmelman AC
Nature; 2020 May; 581(7806):100-105. PubMed ID: 32376951
[TBL] [Abstract][Full Text] [Related]
9. The Hippo Pathway Component TAZ Promotes Immune Evasion in Human Cancer through PD-L1.
Janse van Rensburg HJ; Azad T; Ling M; Hao Y; Snetsinger B; Khanal P; Minassian LM; Graham CH; Rauh MJ; Yang X
Cancer Res; 2018 Mar; 78(6):1457-1470. PubMed ID: 29339539
[TBL] [Abstract][Full Text] [Related]
10. WWC proteins mediate LATS1/2 activation by Hippo kinases and imply a tumor suppression strategy.
Qi S; Zhu Y; Liu X; Li P; Wang Y; Zeng Y; Yu A; Wang Y; Sha Z; Zhong Z; Zhu R; Yuan H; Ye D; Huang S; Ling C; Xu Y; Zhou D; Zhang L; Yu FX
Mol Cell; 2022 May; 82(10):1850-1864.e7. PubMed ID: 35429439
[TBL] [Abstract][Full Text] [Related]
11. Lipid kinase PIP5Kα contributes to Hippo pathway activation via interaction with Merlin and by mediating plasma membrane targeting of LATS1.
Le TPH; Nguyen NTT; Le DDT; Anwar MA; Lee SY
Cell Commun Signal; 2023 Jun; 21(1):149. PubMed ID: 37337213
[TBL] [Abstract][Full Text] [Related]
12. Loss of interferon-gamma inducibility of the MHC class II antigen processing pathway in head and neck cancer: evidence for post-transcriptional as well as epigenetic regulation.
Meissner M; Whiteside TL; van Kuik-Romein P; Valesky EM; van den Elsen PJ; Kaufmann R; Seliger B
Br J Dermatol; 2008 May; 158(5):930-40. PubMed ID: 18284388
[TBL] [Abstract][Full Text] [Related]
13. Interferon-α promotes MHC I antigen presentation of islet β cells through STAT1-IRF7 pathway in type 1 diabetes.
Jiang H; Li Y; Shen M; Liang Y; Qian Y; Dai H; Xu K; Xu X; Lv H; Zhang J; Yang T; Fu Q
Immunology; 2022 Jun; 166(2):210-221. PubMed ID: 35298836
[TBL] [Abstract][Full Text] [Related]
14. Calmodulin activates the Hippo signaling pathway by promoting LATS1 kinase-mediated inhibitory phosphorylation of the transcriptional coactivator YAP.
Thines L; Gorisse L; Li Z; Sayedyahossein S; Sacks DB
J Biol Chem; 2022 May; 298(5):101839. PubMed ID: 35307353
[TBL] [Abstract][Full Text] [Related]
15. Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation.
Dhatchinamoorthy K; Colbert JD; Rock KL
Front Immunol; 2021; 12():636568. PubMed ID: 33767702
[TBL] [Abstract][Full Text] [Related]
16. Histone methyltransferase WHSC1 loss dampens MHC-I antigen presentation pathway to impair IFN-γ-stimulated antitumor immunity.
Ren J; Li N; Pei S; Lian Y; Li L; Peng Y; Liu Q; Guo J; Wang X; Han Y; Zhang G; Wang H; Li Y; Jiang J; Li Q; Tan M; Peng J; Hu G; Xiao Y; Li X; Lin M; Qin J
J Clin Invest; 2022 Apr; 132(8):. PubMed ID: 35230972
[TBL] [Abstract][Full Text] [Related]
17. NLRC5 regulates expression of MHC-I and provides a target for anti-tumor immunity in transmissible cancers.
Ong CEB; Patchett AL; Darby JM; Chen J; Liu GS; Lyons AB; Woods GM; Flies AS
J Cancer Res Clin Oncol; 2021 Jul; 147(7):1973-1991. PubMed ID: 33797607
[TBL] [Abstract][Full Text] [Related]
18. Immune selection in murine tumors. Ph.d thesis.
Svane IM; Engel AM
APMIS Suppl; 2003; (106):1-46. PubMed ID: 12739251
[TBL] [Abstract][Full Text] [Related]
19. Proteasome inhibitors restore the STAT1 pathway and enhance the expression of MHC class I on human colon cancer cells.
Liang YH; Chen KH; Tsai JH; Cheng YM; Lee CC; Kao CH; Chan KY; Chen YT; Hsu WL; Yeh KH
J Biomed Sci; 2021 Nov; 28(1):75. PubMed ID: 34758826
[TBL] [Abstract][Full Text] [Related]
20. The N6-methyladenosine METTL3 regulates tumorigenesis and glycolysis by mediating m6A methylation of the tumor suppressor LATS1 in breast cancer.
Xu Y; Song M; Hong Z; Chen W; Zhang Q; Zhou J; Yang C; He Z; Yu J; Peng X; Zhu Q; Li S; Ji K; Liu M; Zuo Q
J Exp Clin Cancer Res; 2023 Jan; 42(1):10. PubMed ID: 36609396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
